| Literature DB >> 35832708 |
Ibadete Bytyçi1,2,3, Gani Bajraktari1,2,4, Michael Y Henein1,5.
Abstract
Introduction: In responders, cardiac resynchronisation therapy (CRT) results in improved left ventricular (LV) function and reduced atrial arrhythmia. The aim of this meta-analysis was to assess the potential relationship between the left atrium (LA) volume and CRT response. Material and methods: We systematically searched all electronic databases up to August 2018 in order to select clinical trials and observational studies that assessed the predictive value of LA volume index (LAVI) of CRT response. Left ventricular end-systolic volume (LVESV) reduction ≥ 15 ml and/or LV ejection fraction (EF) increase ≥ 10% were the documented criteria for positive CRT response.Entities:
Keywords: cardiac resynchronisation therapy; cardiac resynchronisation therapy non-responders; cardiac resynchronisation therapy responders; left atrial volume index
Year: 2020 PMID: 35832708 PMCID: PMC9266875 DOI: 10.5114/aoms.2019.91511
Source DB: PubMed Journal: Arch Med Sci ISSN: 1734-1922 Impact factor: 3.707
Main characteristics of studies included in the analysis
| Study, year | Study design | Type of intervention | Inclusion criteria | Exclusion criteria | Key endpoints | Echo-cardiography | Criteria for CRT respond | Follow-up |
|---|---|---|---|---|---|---|---|---|
| Marsan | Prospective | CRT-D | LV ≤ 35%, | Patients with | LA and LV | 3DE | LVESV ≥ 15% | 6 mo |
| Donal | Prospective | CRT | HFrEF, | Patients with AF | LA | 2DE | LVESV ≥ 15% | 6 mo |
| Shanks | Prospective | CRT | HFrEF, | NR | Clinical and | 2DE | LVESV ≥ 15% | 40 mo |
| Hsu | Clinical | CRT-D | CMP ischemic | Patients with | Clinical and | 2DE | LVEF ≥ 10% | 12 mo |
| Imamura | Prospective | CRT-D | LV ≤ 35%, | Patients with | LA | 2DE | LVEF ≥ 10% | 6 mo |
| Feneon | Prospective | CRT | LV ≤ 35%, | Patients with | LA | 2DE | LVESV ≥ 15% | 6 mo |
| van ‘t | Prospective | CRT | Patients eligible to | NR | MACE | 2DE | LVESV ≥ 15% | 14 mo |
| Kloosterman | Retrospective | CRT | Eligibility | NR | LA | 2DE | LVESV ≥ 15% | 6 mo |
| Badran | Prospective | CRT | LV ≤ 35%, | Patients with | LA | 2DE | LVESV ≥ 15% | 3 mo |
| Hansen | Clinical | CRT | LV ≤ 35%, | Recently MI | LA | 2DE | LVESV ≥ 15% | 6 mo |
HF – heart failure, HFrEF – heart failure with reduced ejection fraction, CRT – cardiac resynchronisation therapy, LV – left ventricle, EF – ejection fraction, AF – atrial fibrillation, MI – myocardial infraction, CRF – chronic renal failure, MR – mitral regurgitation, 3DE – three-dimensional echocardiography, 2DE – two-dimensional echocardiography, MACE – major cardiac events, LVESV – left ventricle end systolic volume, NR – non-reported, mo – months.
Main characteristics of patients enrolled among trials included in the analysis
| Study, year | Arms | No. | Age [year] | Male (%) | QRS duration [ms] | NYHA functional class | Ischemic aetiology (%) | Mean change of LAVI % | Mean change of LVESV % | Mean change of LVEF % |
|---|---|---|---|---|---|---|---|---|---|---|
| Marsan | R | 34 | 65 ±7 | 78 | 142 ±28 | 3.0 ±0.5 | NR | –6 | –42 | –9 |
| Non-R | 17 | 67 ±10 | 70 | 154 ±31 | 3.0 ±0.4 | NR | 0 | NR | NR | |
| Donal | R | 23 | 67 ±10.4 | 76 | NR | 3.2 ±0.6 | NR | –6.45 | NR | NR |
| Non-R | 23 | 1.5 | NR | NR | ||||||
| Shanks | R | 327 | 66.2 ±10.3 | 74.3 | 156.0 ±32.5 | 2.7 ±0.6 | 53.2 | NR | NR | NR |
| Non-R | 254 | 66.5 ± 9.6 | 81.9 | 150.6 ±29.9 | 2.8 ±0.6 | 69.7 | NR | NR | NR | |
| Hsu | R | 191 | 63.6 ±11.8 | 83 | 153.9 ±18.1 | NR | 62 | –4.32 | –32.4 | –4.1 |
| Non-R | 562 | 64.2 ±10.9 | 70 | 159.7 ±20.1 | NR | 59 | 2.15 | NR | NR | |
| Imamura | R | 11 | 53 ±15 | 73 | 148 ±49 | N-IV = 34% | 9 | NR | NR | NR |
| Non-R | 56 | 49 ±12 | 84 | 141 ±33 | N-IV = 45% | 14 | NR | NR | NR | |
| Feneon | R | 54 | 62.3 ±10 | 63 | 163 ±27 | N-II = 24% | 18.6 | NR | NR | NR |
| Non-R | 25 | 66.5 ±10 | 80 | 158 ±30 | N-II = 22% | 60 | NR | NR | NR | |
| van ‘t | R | 63 | 64.6 ±11.0 | 62 | 160 ±26 | N-IV = 2% | 83 | –7.2 | –72 | –10 |
| Non-R | 12 | 70.6 ±7.0 | 82 | 166 ±25 | N-IV = 8.5% | 37 | –2.3 | NR | NR | |
| Kloosterman | R | 201 | 65.4 ±11 | 70 | 162 ±24 | N-IV = 24% | 5 | –2 | –75 | –11.2 |
| Non-R | 164 | 64 ±11 | 75 | 158 ±22 | N-IV = 25% | 3 | 2.5 | NR | NR | |
| Badran | R | 24 | 56 ±9.8 | 71 | NR | N-IV = 33% | 29 | –5 | –35.2 | –9.6 |
| Non-R | 13 | 53 ±9.5 | 69 | NR | N-IV = 46% | 23 | –4.5 | NR | NR | |
| Hansen | R | 114 | 69.4 ±9 | 80 | 166.2 ±23.0 | N-IV = 3% | 50 | –4.4 | –50 | NR |
| Non-R | 24 | –2 | NR | NR |
R – responder, Non-R – non-responder, LAVI – left atrial volume indexed, LVESV – left ventricle end systolic volume, LVEF – left ventricle ejection fraction, NR – non-reported,
only whole group represented. Mean changes of LVESV and LVEF were represented only in CRT responders.
Figure 1Comparison of baseline LAVI in the group of patients with CRT response vs. CRT non-response
Figure 2A – Mean changed LAVI in patients with CRT response; B – mean change LAVI in patients with CRT non-response
Figure 3Meta-regression of LAVI: A – The meta-regression analysis showed that the % mean change of LAVI was related to changes of LVESV; B – The meta-regression analysis showed that the % mean change of LAVI was related to changes of LVEF after CRT
Figure 4The baseline cut-off of LAVI < 34 ml/m2 in prediction of CRT response: A – Forest plot, B – SROC curve